INTRODUCTION
============

The asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is a common condition that shares features of both asthma and COPD.[@B1] The proportion of COPD among asthmatic patients has been reported to be up to 50%,[@B2] and coexisting COPD has a substantial impact on the natural course of asthma. Previous reports have found that coexisting COPD is associated with frequent exacerbations of asthma, reduced quality of life, and increased use of healthcare resources in patients with asthma.[@B3][@B4][@B5][@B6] COPD, in conjunction with asthma, is also associated with increased mortality compared to patients with only asthma and no other respiratory conditions.[@B7]

Severe asthma is diagnosed in 5%-10% of asthma patients,[@B8] and 20%-60% of patients with severe asthma regularly use systemic corticosteroids (CSs)[@B9][@B10][@B11] and are defined as patients with CS-dependent asthma. This condition is one of the most serious forms of severe asthma and has an increased risk of CS-related comorbidities, exacerbations, healthcare use, and most importantly, mortality in asthmatic patients.[@B12]

A significant proportion of patients with severe asthma are considered to have COPD. A survey of asthma experts has reported that about 38% of severe asthmatic patients are expected to have ACO.[@B13] Another study using a severe asthma registry to evaluate the proportion of asthmatic patients with COPD found that about one-fourth of patients with severe asthma were diagnosed with ACO based on clinical features such as smoking history and persistent airflow limitations.[@B14] This study also found that ACO patients used more oral CS medication than those with only severe asthma and had more frequent emergency department (ED) visits in the previous year, suggesting poor asthma control and, perhaps, poor prognoses in this population. However, there are few longitudinal follow-up data addressing the prognosis of ACO in the context of patients with CS-dependent severe asthma.

We recently established a retrospective cohort of CS-dependent asthmatic patients using the Korea National Health Insurance Service (NHIS) database.[@B12] Using this database, we evaluated the impact of coexisting COPD on mortality and healthcare use in patients with CS-dependent asthma.

MATERIALS AND METHODS
=====================

Study design and study population
---------------------------------

In Korea, mandatory health care for almost all Korean citizens (nearly 50 million subjects) is provided by the NHIS. Accordingly, the NHIS collects the following health data for its insured subjects: 1) outpatient visit and admission records, 2) major and minor diagnoses, 3) drug prescriptions, 4) national health examination data, and 5) death.[@B15]

In our previous study, we constructed a retrospective CS-dependent asthma cohort composed of 8,334 patients aged 18 years or older for whom patient records were available for the period between January 1, 2005 to December 31, 2005.[@B12] Using this dataset and subjects, we enrolled 8,021 patients aged 40 years or older in the study. Patients were followed until the date of death or December 31, 2015, whichever was sooner.

This study was approved by the Institutional Review Board (IRB) of our institution (IRB number: HYUH 2017-09-051). The requirement for informed consent from the participants was waived because the NHIS database was constructed after anonymization.

Definitions
-----------

We defined adult asthma according to the following criteria: 1) age ≥ 18 years, 2) ≥ 2 claims under the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes J45--J46, and 3) ≥ 1 claim for the use of asthma-related drugs, which include inhaled or systemic CS medication, bronchodilators, leukotriene receptor antagonists, and xanthine derivatives (*e.g.,* theophylline) during the baseline period (12 months after the diagnosis of asthma between January 1 and December 31 of 2005).[@B12][@B16][@B17] CS-dependent asthma was defined as the presence of asthma and prescription of systemic CS under codes ICD-10 J45--J46 for at least 6 months in the baseline period.[@B18][@B19][@B20] COPD was defined according to the following criteria: 1) aged 40 or older[@B21] and 2) at least one claim under a major diagnosis of COPD during the baseline period.

We defined the baseline comorbidities as comorbidities with ≥ 1 claim under ICD-10 codes as a major diagnosis during the baseline period as follows: diabetes mellitus (E10--E14), Cushing\'s disease (E24), adrenal insufficiency (E27.3--E27.4), bone necrosis (M87), osteoporosis (M80--M82), vertebral or pelvic fracture (S22.0--S22.1, S32.0, and M48.4), pneumonia (J12--J18), tuberculosis (A15--A19), hypertension (I10--I15), angina (I20), myocardial infarction (I21), heart failure (I50), peptic ulcer (K25--K27), gastrointestinal bleeding (K92.0--K92.2), glaucoma (H40 and H42), and cataract (H25, H26, and H28).

Regarding the mortality date and cause of mortality, we used data provided by the Statistics Korea, an initiative of the Ministry of Strategy and Finance of Korea.[@B15] We classified the causes of deaths according to the following 10 categories: 1) respiratory diseases (J00--J99), 2) cardiovascular diseases (I00--I99), 3) malignant neoplasms (C00--C97), 4) injury, poisoning, and external causes (S00--T98), 5) endocrine diseases (E00--E90), 6) gastrointestinal diseases (K00--K93), 7) neurologic diseases (G00--G99), 8) mental and behavioral disorders (F00--F99), 9) musculoskeletal and connective tissue diseases (M00--M99), and 10) miscellaneous.

Regarding healthcare use, we defined an asthma-related ED visit and hospitalization as a visit to an ED and admission to a hospital under ICD-10 codes J45--J46 as a major or minor diagnosis during the follow-up period, respectively.

Main outcomes and measures
--------------------------

The primary outcome was to evaluate the impact of coexisting COPD on all-cause mortality in patients with CS-dependent asthma during the follow-up period. The secondary outcome was to evaluate the cause of mortality in patients with CS-dependent asthma with COPD.

Statistical analysis
--------------------

We used the McNemar test to compare the baseline characteristics (age group, sex, type of insurances, Charlson comorbidity index \[CCI\],[@B22] comorbidities, and asthma-related medications) of patients with CS-dependent asthma according to the presence or absence of COPD. We used Kaplan-Meier survival analysis to estimate survival curves and used the log-rank test to compare survival between the groups. Cox proportional hazard regression modeling was used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) for the main outcomes in patients with CS-dependent asthma and COPD relative to those without COPD. We further adjusted for the effect of age, sex, type of insurance, and CCI using the multivariable Cox proportional regression model.

To assess the effect of coexisting COPD on mortality and healthcare use, we compared the incidence rates (per 100,000 person-years \[PY\]) of mortality and healthcare use in patients with COPD vs. those without COPD by the normal approximation test for binomials.

We also determined the HRs for each cause of mortality. We used a cause-specific and subdistribution proportional hazards regression model to account for competing risks caused by mortality due to other causes.[@B23] We considered 2-sided *P* values \< 0.05 statistically significant.

As the baseline characteristics of patients with CS-dependent asthma and COPD and those without COPD were significantly different, propensity score matching was used to reduce selection bias, and patients with COPD were matched 1:1 with patients without COPD with regard to age, sex, and CCI ([Supplementary Fig. S1](#S3){ref-type="supplementary-material"} and [Supplementary Table S1](#S1){ref-type="supplementary-material"}). Using the matched population, we undertook the same analyses as those performed in the unmatched population. The characteristics of the 2 populations were compared using standardized mean differences. Standardized mean differences \> 0.10 were considered unbalanced.[@B24]

All analyses in our study were performed using SAS^®^ 9.4 (SAS Institute, Cary, NC, USA).

RESULTS
=======

Population
----------

The baseline cohort comprised 8,021 patients at least of 40 years of age with CS-dependent asthma, of whom 3,121 (38.9%) also had COPD. Patients with COPD were older (mean 69.2 years vs. 66.0 years, *P* \< 0.001) and were predominantly male (68.9% vs. 48.2%, *P* \< 0.001), were more likely to use medical aid as their insurance (7.7% vs. 3.1%, *P* \< 0.001), and had higher CCI values (mean 3.9 vs. 3.7, *P* \< 0.001) ([Table 1](#T1){ref-type="table"}). Regarding comorbidities, there were no significant differences in comorbidities, including diabetes mellitus, adrenal insufficiency, bone necrosis, osteoporosis, gastrointestinal bleeding, glaucoma, or cataract. While vertebral or pelvic fracture (6.3% vs. 4.3%, *P* \< 0.001), previous history of pneumonia (46.3% vs. 21.2%, *P* \< 0.001), tuberculosis (11.5% vs. 4.5%, *P* \< 0.001), myocardial infarction (3.8% vs. 2.5%, *P* \< 0.001), congestive heart failure (15.6% vs. 10.5%, *P* \< 0.001), and peptic ulcer disease (48.0% vs. 39.8%, *P* \< 0.001) were more frequent among patients with COPD compared to those without in our cohort, Cushing\'s syndrome (3.2% vs. 2.0%, *P* = 0.002) and hypertension (57.8% vs. 54.4%, *P* = 0.003) were more frequent among patients without COPD compared to those with.

###### Baseline demographics

![](aair-12-821-i001)

  Variables                         CS-dependent asthma              *P* value                                                    
  --------------------------------- -------------------------------- ------------------------------ -------------- -------------- ----------
  Age (yr)                          69.2 ± 9.6                       66.0 ± 11.3                    \< 0.001                      
                                    Forties                          115 (3.7)                      465 (9.5)                     
                                    Fifties                          373 (12.0)                     928 (18.9)                    
                                    Sixties                          981 (31.4)                     1,486 (30.3)                  
                                    ≥ Seventies                      1,652 (52.9)                   2,021 (41.2)                  
  Sex                                                                                               \< 0.001                      
                                    Male                             2,149 (68.9)                   2,361 (48.2)                  
                                    Female                           972 (31.1)                     2,539 (51.8)                  
  Type of insurance                                                                                 \< 0.001                      
                                    Self-employed health insurance   1,206 (38.6)                   2,023 (41.3)                  
                                    Employee health insurance        1,675 (53.7)                   2,723 (55.6)                  
                                    Medical aid                      240 (7.7)                      154 (3.1)                     
  Charlson comorbidities index      3.9 ± 2.4                        3.7 ± 2.3                      \< 0.001                      
  Comorbidities                                                                                                                   
                                    Metabolic disease                1,057 (33.9)                   1,593 (32.5)   0.208          
                                                                     Diabetes mellitus              1,008 (32.3)   1,520 (31.0)   0.230
                                                                     Cushing\'s syndrome            63 (2.0)       157 (3.2)      0.002
                                                                     Adrenal insufficiency          51 (1.6)       89 (1.8)       0.543
                                    Bone disease                     650 (20.8)                     1,041 (21.2)   0.654          
                                                                     Bone necrosis                  17 (0.5)       16 (0.3)       0.137
                                                                     Osteoporosis                   588 (18.8)     967 (19.7)     0.323
                                                                     Vertebral or pelvic fracture   195 (6.3)      210 (4.3)      \< 0.001
                                    Infectious disease               1,525 (48.9)                   1,133 (23.1)   \< 0.001       
                                                                     Pneumonia                      1,445 (46.3)   1,040 (21.2)   \< 0.001
                                                                     Tuberculosis                   359 (11.5)     222 (4.5)      \< 0.001
                                    Cardiovascular disease           1,907 (61.1)                   3,006 (61.4)   0.826          
                                                                     Hypertension                   1,697 (54.4)   2,831 (57.8)   0.003
                                                                     Angina                         439 (14.1)     620 (12.7)     0.068
                                                                     Myocardial infarction          118 (3.8)      120 (2.5)      0.001
                                                                     Congestive heart failure       487 (15.6)     512 (10.5)     \< 0.001
                                    Gastrointestinal disease         1,508 (48.3)                   1,964 (40.1)   \< 0.001       
                                                                     Peptic ulcer disease           1,498 (48.0)   1,950 (39.8)   \< 0.001
                                                                     Gastrointestinal bleeding      28 (0.9)       49 (1.0)       0.645
                                    Ophthalmologic disease           155 (5.0)                      223 (4.6)      0.392          
                                                                     Glaucoma                       22 (0.7)       31 (0.6)       0.697
                                                                     Cataract                       140 (4.5)      196 (4.0)      0.290
  Medication during follow-up^\*^                                                                   \< 0.001                      
                                    Any ICS                          2,583 (82.8)                   3,430 (70.0)   \< 0.001       
                                    Any LABA                         2,257 (72.3)                   2,968 (60.6)   \< 0.001       
                                    Any LAMA                         1,109 (35.5)                   722 (14.7)     \< 0.001       
                                    SABA                             2,848 (91.3)                   3,735 (76.2)   \< 0.001       
                                    LTRA                             1,836 (58.8)                   2,894 (59.1)   0.836          

Data are presented as frequency (%) and mean ± standard deviation.

COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β~2~ agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β~2~ agonist; LTRA, leukotriene receptor antagonist.

^\*^Some patients received more than one medication.

The proportion of patients who used inhalers, including any inhaled CS (82.8% vs. 70.0%, *P* \< 0.001), long-acting β~2~ agonist (LABA) (72.3% vs. 60.6%, *P* \< 0.001), long-acting muscarinic antagonist (LAMA) (35.5% vs. 14.7%, *P* \< 0.001), or short-acting β~2~ agonist (91.3% vs. 76.2%, *P* \< 0.001), were significantly greater in patients with COPD than in those without. There was no significant difference in the use of leukotriene receptor antagonists between the 2 groups.

Mortality
---------

As shown in the survival analyses ([Figure](#F1){ref-type="fig"}), all-cause mortality was significantly greater in patients with COPD than in those without (9,955/100,000 PY vs. 5,585/100,100 PY, *P* \< 0.001). As shown in [Table 2](#T2){ref-type="table"}, in univariable Cox regression analyses, patients with COPD were 1.77-fold (95% CI, 1.66--1.88) were more likely to die during the follow-up period. Regardless of the adjustment for covariables, the HRs remained significantly increased: the HRs in model 1 for which age and sex were adjusted were 1.32 (95% CI, 1.24-1.41), while the HR in model 2 in which type of insurance was further adjusted was 1.30 (95% CI, 1.22-1.39), and was 1.29 (95% CI, 1.21-1.38) in model 3 for which CCI was further adjusted. Subgroup analyses performed by the sex and age groups produced similar results.

![Kaplan-Meier survival plot of time to death.\
COPD, chronic obstructive pulmonary disease.](aair-12-821-g001){#F1}

###### The effects of COPD on mortality in patients with CS-dependent asthma
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  Variables                Mortality (/100,000 PY)              HR for mortality (95% CI)                                                               
  ------------------------ ------------------------------------ --------------------------- ------------------- ------------------- ------------------- -------------------
  Overall population^\*^   7,085                                                                                                                        
                           CS-independent asthma without COPD   9,955                       Reference           Reference           Reference           Reference
                           CS-independent asthma with COPD      5,585                       1.77 (1.66--1.88)   1.32 (1.24--1.41)   1.30 (1.22--1.39)   1.29 (1.21--1.38)
  Male^†^                  8,223                                                                                                                        
                           CS-independent asthma without COPD   6,207                       Reference           Reference           Reference           Reference
                           CS-independent asthma with COPD      10,964                      1.75 (1.61--1.89)   1.36 (1.25--1.47)   1.33 (1.23--1.45)   1.33 (1.23--1.44)
  Female^†^                5,776                                                                                                                        
                           CS-independent asthma without COPD   5,036                       Reference           Reference           Reference           Reference
                           CS-independent asthma with COPD      7,992                       1.58 (1.42--1.76)   1.27 (1.14--1.41)   1.25 (1.12--1.39)   1.23 (1.11--1.37)
  Age \< 60^‡^             1,937                                                                                                                        
                           CS-independent asthma without COPD   1,407                       Reference           Reference           Reference           Reference
                           CS-independent asthma with COPD      3,653                       2.60 (2.09--3.23)   2.26 (1.81--2.82)   2.13 (1.70--2.67)   2.09 (1.66--2.62)
  Age ≥ 60^‡^              9,292                                                                                                                        
                           CS-independent asthma without COPD   7,826                       Reference           Reference           Reference           Reference
                           CS-independent asthma with COPD      11,593                      1.47 (1.38--1.57)   1.26 (1.18--1.35)   1.24 (1.16--1.33)   1.24 (1.16--1.32)

COPD, chronic obstructive pulmonary disease; CS, corticosteroid; HR, hazard ratio; CI, confidence interval.

^\*^Age and sex were adjusted in model 1. Age, sex, and type of insurance were adjusted in model 2. Age, sex, type of insurance, and Charlson comorbidities index were adjusted in model 3; ^†^In subgroup analyses by sex, the above-mentioned variables (except sex) were adjusted in each model; ^‡^In subgroup analyses by age, the above-mentioned variables (except age) were adjusted in each model.

After matching ([Supplementary Table S1](#S1){ref-type="supplementary-material"}), in the survival analyses, patients with COPD had an increased risk of mortality compared to those without (HR, 1.37; 95% CI, 1.26-1.49).

Cause of mortality
------------------

The most common etiology of mortality in CS-dependent asthma patients was respiratory diseases (44.1%), followed by cardiovascular diseases (16.8%), malignancy (13.5%), injury, poisoning, and external causes (4.5%), and endocrine diseases (3.3%) ([Table 3](#T3){ref-type="table"}).

###### HRs (95% CIs) for mortality in patients with CS-dependent asthma and COPD relative to those without COPD
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  Variables                                        Total^\*^ (n = 3,939)                Without COPD (n = 2,042)   With COPD (n = 1,897)   Cause-specific HR (95% CI)   Cause-specific subdistribution HR (95% CI)^†^   
  ------------------------------------------------ ------------------------------------ -------------------------- ----------------------- ---------------------------- ----------------------------------------------- -------------------
  Respiratory diseases                             1,736 (44.1)                         712/1,736 (41.0)           1,024/1,736 (59.0)      1.91 (1.73--2.11)            1.96 (1.77--2.17)                               
                                                   Chronic lower respiratory diseases   1,463 (37.1)               542/1,463 (37.0)        921/1,463 (63.0)             2.23 (2.00--2.49)                               2.30 (2.06--2.57)
                                                   Pneumonia                            132 (3.4)                  85/132 (64.4)           47/132 (35.6)                0.73 (0.51--1.06)                               0.68 (0.47--0.99)
  Cardiovascular diseases                          661 (16.8)                           423/661 (64.0)             238/661 (36.0)          0.84 (0.71--0.99)            0.79 (0.67--0.93)                               
                                                   Hypertension                         73 (1.9)                   49/73 (67.1)            24/73 (32.9)                 0.74 (0.44--1.22)                               0.73 (0.45--1.19)
                                                   Ischemic heart disease               196 (5.0)                  125/196 (63.8)          71/196 (36.2)                0.83 (0.61--1.12)                               0.80 (0.59--1.09)
                                                   Heart failure                        77 (2.0)                   53/77 (68.8)            24/77 (31.2)                 0.70 (0.43--1.15)                               0.68 (0.41--1.12)
                                                   Cerebrovascular disease              199 (5.1)                  132/199 (66.3)          67/199 (33.7)                0.74 (0.55--1.00)                               0.70 (0.51--0.96)
  Malignant neoplasms                              532 (13.5)                           284/532 (53.4)             248/532 (46.6)          1.19 (1.00--1.42)            1.10 (0.92--1.31)                               
                                                   Lung cancer                          217 (5.5)                  102/217 (47.0)          115/217 (53.0)               1.46 (1.11--1.92)                               1.34 (1.02--1.78)
                                                   Other cancer                         315 (8.0)                  182/315 (57.8)          133/315 (42.2)               1.03 (0.82--1.30)                               0.94 (0.75--1.19)
  Injury, poisoning, and external causes           179 (4.5)                            100/179 (55.9)             79/179 (44.1)           1.07 (0.79--1.46)            0.99 (0.73--1.35)                               
  Endocrine diseases                               130 (3.3)                            102/130 (78.5)             28/130 (21.5)           0.39 (0.25--0.60)            0.38 (0.24--0.59)                               
                                                   Diabetes mellitus                    121 (3.1)                  95/121 (78.5)           26/121 (21.5)                0.39 (0.25--0.61)                               0.37 (0.23--0.60)
  Gastrointestinal diseases                        75 (1.9)                             49/75 (65.3)               26/75 (34.7)            0.83 (0.51--1.35)            0.78 (0.47--1.28)                               
  Neurologic diseases                              48 (1.2)                             35/48 (72.9)               13/48 (27.1)            0.51 (0.26--0.98)            0.47 (0.24--0.90)                               
  Mental and behavioral disorders                  31 (0.8)                             18/31 (58.1)               13/31 (41.9)            1.22 (0.59--2.54)            1.22 (0.58--2.58)                               
  Musculoskeletal and connective tissue diseases   21 (0.5)                             13/21 (61.9)               8/21 (38.1)             1.15 (0.46--2.88)            1.11 (0.46--2.65)                               
                                                   Osteoporosis                         11 (0.3)                   7/11 (63.6)             4/11 (36.4)                  0.84 (0.24--3.01)                               0.83 (0.25--2.81)
  Other                                            526 (13.4)                           306/526 (58.2)             220/526 (41.8)          1.02 (0.86--1.23)            0.97 (0.80--1.16)                               

Data are presented as number (%) and risk ratios (95% CI).

CS, corticosteroid; HR, hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease.

^\*^Thirty-five patients who did not have information regarding cause of mortality were excluded; ^†^Subdistribution HR of the disease-specific cause of mortality was calculated with other causes of mortality as competing risks.

The cause-specific mortality risks associated with respiratory diseases (HR, 1.91; 95% CI, 1.73--2.11), including chronic lower respiratory diseases such as asthma, bronchiectasis, or COPD itself (HR, 2.23; 95% CI, 2.00--2.49) and lung cancer (HR, 1.46; 95% CI, 1.11--1.92), were greater in patients with COPD compared with those without COPD, which was consistent with the analyses considering competing risks caused by other diseases: respiratory diseases (subdistribution HR, 1.96; 95% CI, 1.77--2.17), including chronic lower respiratory diseases (subdistribution HR, 2.30; 95% CI, 2.06--2.57) and lung cancer (subdistribution HR, 1.34; 95% CI, 1.02--1.78).

Similarly, after propensity matching, the cause-specific HRs and subdistribution HRs for mortality related to respiratory diseases (HR, 1.88; 95% CI, 1.68--2.10 and subdistribution HR, 1.87; 95% CI, 1.67--2.08) and lung cancer (HR, 1.49; 95% CI, 1.10--2.00 and subdistribution HR, 1.35; 95% CI, 1.01--1.82) were significantly increased in patients with COPD relative to those without COPD ([Supplementary Table S2](#S2){ref-type="supplementary-material"}).

Healthcare use
--------------

The rates of annual ED visits (per 100,000 PY; 32,328 vs. 24,248 PY; *P* \< 0.001), including asthma-related ED visits (10,970 PY vs. 6,163 PY; *P* \< 0.001) and annual hospitalizations (323,882 PY vs. 200,597 PY; *P* \< 0.001), asthma-related hospitalizations (112,684 PY vs. 53,343 PY; *P* \< 0.001), were greater in patients with COPD than in those without. Similar results were obtained in propensity-matching analyses (data not shown).

DISCUSSION
==========

This study evaluated the impact of coexisting physician-diagnosed COPD on long-term outcomes in patients with CS-dependent asthma using a large-scale, nationwide population-based, longitudinal cohort study. We showed that coexisting COPD is associated with increased risks of mortality, ED visits, and hospitalization. In addition, we also showed that CS-dependent asthmatic patients with COPD had increased risks of death due to chronic lower respiratory disease and lung cancer.

Coexisting COPD has a negative impact on patients with severe asthma. Previous studies revealed that patients with severe asthma and COPD are more likely to be older, male, and ever-smokers and to have lower lung function and exacerbations needing ER visits.[@B14][@B25] Similarly, our study showed that patients with CS-dependent asthma and COPD were older and had a higher proportion of males, lower socioeconomic status estimated by type of insurance, and higher CCI values than those without COPD. The major advantage of our study was that the negative impact of coexisting COPD on treatment outcomes in patients with CS-dependent asthma, including mortality, ED visits, and hospitalization, remained even after adjusting for these factors. The findings are strengthened by our use of a large population-based longitudinal cohort study design and by the similarity of the results obtained with and without the use of propensity matching.

As patients with severe asthma display many of the features of COPD, and there is, therefore, a considerable overlap between the 2 conditions, it is often challenging to distinguish severe asthma from COPD. Surprisingly, in this study, about 40% of patients with CS-dependent asthma were diagnosed as also having COPD by their attending physicians. Although the reasons why these patients were classified as having COPD are unclear, our study results suggest that early recognition of COPD in patients with CS-dependent asthma is important in real-world clinics especially when considering the potential vulnerabilities (older age, high CCI, and lower socioeconomic status), substantial healthcare use, and increased mortality among these patients. However, it is not known whether early diagnosis and management of coexisting COPD might be helpful in preventing poor treatment outcomes in patients with severe asthma. Further studies on this issue are urgently needed.

In our study, patients with CS-dependent asthma and COPD were more likely to die due to respiratory diseases and due to lung cancer than those without. Recognizing the causes of deaths and determining appropriate preventive strategies on the basis of the study results using a large-population database remain essential considerations to improve treatment outcomes of disease. Accordingly, our results emphasize the importance of disease control in patients with CS-dependent asthma and COPD. In our study, despite systemic CS use due to uncontrolled disease and recognition of COPD, the attending physicians prescribed LAMA to only about one-third of their patients. Although there is no direct evidence that the additional use of LAMA can reduce mortality in CS-dependent patients with severe asthma and COPD, there is limited evidence supporting the use of LAMA in addition to inhaled corticosteroid/LABA in patients with severe asthma.[@B25][@B26] As our study population had COPD, we also need to consider the impact of inhaler treatment on mortality in the context of COPD. Recent studies showed that triple therapy (in a single inhaler) showed improved survival after 1 year of treatment in patients with moderate-to-severe COPD.[@B27][@B28] Our results, together with previous study findings, may indicate that we need to build a strategy to optimize the medical treatment of patients with severe asthma and COPD.

One of the most important causes of death in COPD patients is lung cancer. A previous study reported that patients with COPD were about 3.2-fold more likely to die due to lung cancer than those without.[@B29] In our study, the cause-specific HR of mortality due to lung cancer was significantly increased in patients with COPD compared to those without. These results may imply that the surveillance of lung cancer development after recognition of COPD in CS-dependent patients with asthma and COPD is important. Other efforts to reduce exposure to risk factors for lung cancer, such as smoking, may also need to be emphasized.

This study had several limitations. First, this study enrolled subjects from a single country. As the prevalence of asthma and COPD according to age and sex and the patterns of drug prescription differ by ethnicity and country, future studies considering the influence of those factors are needed. Secondly, the baseline characteristics of patients with and without COPD were quite different. Thus, we verified our results using 2 methods (*i.e*., adjustment for covariables and propensity matching methods). Regardless of the statistical method used, our study results consistently showed that patients with COPD had a higher risk of mortality and increased healthcare use. Thirdly, we used only the ICD-10 codes to define COPD since spirometric data were not available. Accordingly, the severity of COPD (*i.e*., Global Initiative for Chronic Obstructive Lung Disease severity) could not be taken into consideration in our analyses. However, it is notable that the recognition of COPD by attending physicians in real-world clinics have significantly reflected the outcomes in this population. Fourthly, we could not analyze the impact of important confounders, such as occupation, education, and smoking habits, as the claims data did not include these variables. However, we included the type of insurance which may have provided partial adjustment for socioeconomic exposure. Despite these limitations, our study was strengthened by the use of a large, nationwide study population.

In conlusion, in this population-based retrospective cohort study, the diagnosis of COPD was associated with a greater rate of mortality in patients with CS-dependent asthma. The main causes of mortality were chronic lower respiratory diseases and lung cancer. The findings suggest that early recognition and proper management of COPD may improve treatment outcomes in patients with CS-dependent asthma.
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Characteristics of patients with CS-dependent asthma COPD vs. those without COPD after propensity score matching
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HRs (95% CIs) for mortality in patients with CS-dependent asthma and COPD relative to those without COPD after matching
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Propensity score overlap between patients with corticosteroid-dependent asthma and COPD and those without COPD.
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